Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
– Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 – – Cybin’s growing intellectual property portfolio comprises more than 80 granted patents and over 230 pending applications – – Patient dosing continues
Cybin to Participate at the 28th Annual Milken Institute Global Conference
– Doug Drysdale, CEO, to appear on panel entitled “The Global Landscape and Opportunities for Medical Breakthroughs,” on May 5, 2025 – TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
– Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment – – Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
– Cybin will leverage Osmind’s 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline – – Osmind is a leading service provider to psychiatry practices in the U.S. focused on advancing psychiatry through technology and
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
– Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) – – PARADIGM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
– Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance – – First program member is Segal Trials, a preferred provider for leading pharmaceutical companies globally
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
– Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (“MDD”) – – Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of MDD – – Received U.S.
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
– Poster presentations highlight clinical data across Cybin’s CYB003 deuterated psilocin and DMT programs – TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to